ArticleBMC neurology2026
Low uric acid predicts severe outcomes in neuronal surface antibody-mediated autoimmune encephalitis.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAutoimmune encephalitis (AE) mediated by neuronal surface antibodies is a severe neuroinflammatory disorder with heterogeneous clinical manifestations. Early identification of patients at risk for severe outcomes, such as intensive care unit (ICU) admission, remains a challenge. Uric acid (UA), known for its dual role in inflammation as both a danger-associated molecular pattern (DAMP) and an antioxidant, has been implicated in various autoimmune diseases, but its prognostic significance in AE has not been systematically explored.
methodsThis retrospective study enrolled 90 patients with neuronal surface antibody-positive AE. Serum UA levels were measured at admission, and clinical outcomes, including Clinical Assessment Scale for Autoimmune Encephalitis (CASE), discharge modified Rankin Scale (mRS) and ICU admission were analyzed. Statistical methods included Spearman correlation, logistic regression, and receiver operating characteristic (ROC) curve analysis to evaluate predictive value of UA.
resultsPatients requiring ICU admission had significantly lower UA levels (median 193.0 vs. 250.0 µmol/L, p = 0.008). UA negatively correlated with CASE scores (r = -0.237, p = 0.024) and discharge mRS (r = -0.267, p = 0.011). Logistic analysis identified UA as a potential adjunct biomarker of ICU admission (yes/no) (OR = 0.985, 95%CI:0.971-1.000, p = 0.044), with an optimal cutoff of 213.5 µmol/L (AUC = 0.703, sensitivity 63.9%, specificity 77.8%). Patients with UA < 213.5 µmol/L were older and had higher CASE scores and worse functional outcomes (p < 0.05).
conclusionDecreased serum UA at admission is associated with increased risk of ICU admission in neuronal surface antibody-mediated AE, and correlate with a more severe disease severity and poorer functional outcomes, suggesting its potential as a prognostic biomarker, possibly reflecting its neuroprotective role.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.